FELDENE is highly protein bound, and therefore, might be expected to displace other protein-bound drugs. Although
this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type
anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients
for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other
highly protein-bound drugs.
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered
in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam
plasma levels .
Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma
lithium levels. It is recommended that plasma lithium levels be monitored when initiating, adjusting and